Vertex Pharmaceuticals (VRTX) Hits New All-Time Low on Failed Clinical Trial
In a statement, Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc / Ma (VRTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Renaissance Technologies Jim Simons | 1,004,888 | $447,376,138 | -15% | 0.6% |
| 2. | 318,800 | $141,929,760 | +16% | 0.02% | |
| 3. | OrbiMed Advisors Samuel Isaly | 210,287 | $93,619,772 | +32% | 2.34% |
| 4. | Adage Capital Management Phill Gross And Robert Atchinson | 178,192 | $79,331,078 | -64% | 0.13% |
| 5. | Squarepoint Ops LLC Maxime Fortin (Cio) | 175,687 | $78,215,852 | +2449% | 0.08% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $389.95 | 5,710 | $2,226,614.50 | 115,968 | 2025-08-06 | Filing | |
| $389.08 | 4,290 | $1,669,153.20 | 110,258 | 2025-08-06 | Filing | |
| $389.84 | 3,366 | $1,312,201.44 | 45,000 | 2025-08-06 | Filing | |
| $389.36 | 1,634 | $636,214.24 | 41,634 | 2025-08-06 | Filing | |
| $196.34 | 4,243 | $833,070.62 | 73,754 | 2021-08-19 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $424.69 | 52 | $22,083.88 | 23,281 | 2025-05-15 | Filing | |
| $505.86 | 400 | $202,344.00 | 4,831 | 2025-05-02 | Filing | |
| $510.00 | 3,231 | $1,647,810.00 | 23,281 | 2025-03-13 | Filing | |
| $500.00 | 3,298 | $1,649,000.00 | 51,671 | 2025-03-10 | Filing | |
| $499.99 | 3,242 | $1,620,967.58 | 51,239 | 2025-03-10 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 28,732,143 | $12,791,428,317 | 1.86% | |
| 2. | 23,973,777 | $10,673,125,520 | 0.17% | |
| 3. | 21,871,945 | $9,737,389,761 | 0.19% | |
| 4. | 16,108,291 | $7,171,363,823 | 1.44% | |
| 5. | 11,775,227 | $5,242,331,060 | 0.2% |
News See All
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q2 2025 Earnings Call Transcript August 4, 2025Vertex Pharmaceuticals Incorporated beats earnings expectations.
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts.
10 Most Undervalued Healthcare Stocks to Buy According to Analysts
The CEO of Pivotal Advisors, Tiffany McGhee, spoke on CNBC on June 27 on what investors should do in light of the current state of the market.
EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks.
Goldman Sachs Healthcare Stocks: Top 10 Stock Picks
The healthcare sector has been under pressure, underperforming the S&P 500 over the past several years.
Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)?
PGIM Jennison Health Sciences Fund released its first quarter 2025 investor letter. A copy of the letter can be downloaded here.
H.C. Wainwright Reaffirms Vertex Buy Rating After ADA Conference Results
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) ranks among the best fundamental stocks to buy according to hedge funds. With a price target of $550, H.C.
Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
Billionaire Hedge Funds
